ATE400274T1 - Hemmstoffe der akt aktivität - Google Patents

Hemmstoffe der akt aktivität

Info

Publication number
ATE400274T1
ATE400274T1 AT02721697T AT02721697T ATE400274T1 AT E400274 T1 ATE400274 T1 AT E400274T1 AT 02721697 T AT02721697 T AT 02721697T AT 02721697 T AT02721697 T AT 02721697T AT E400274 T1 ATE400274 T1 AT E400274T1
Authority
AT
Austria
Prior art keywords
compounds
activity inhibitors
act activity
act
directed
Prior art date
Application number
AT02721697T
Other languages
English (en)
Inventor
Stanley Barnett
Samuel Graham
David Remy
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE400274T1 publication Critical patent/ATE400274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Seeds, Soups, And Other Foods (AREA)
AT02721697T 2001-04-10 2002-04-08 Hemmstoffe der akt aktivität ATE400274T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28278101P 2001-04-10 2001-04-10

Publications (1)

Publication Number Publication Date
ATE400274T1 true ATE400274T1 (de) 2008-07-15

Family

ID=23083087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721697T ATE400274T1 (de) 2001-04-10 2002-04-08 Hemmstoffe der akt aktivität

Country Status (8)

Country Link
US (1) US7034026B2 (de)
EP (1) EP1379251B1 (de)
JP (1) JP4361276B2 (de)
AT (1) ATE400274T1 (de)
AU (1) AU2002252614B2 (de)
CA (1) CA2442270C (de)
DE (1) DE60227492D1 (de)
WO (1) WO2002083138A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086394A1 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
KR101254278B1 (ko) * 2003-04-18 2013-04-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 퀴녹살린 유도체를 이용한 트랜지스터
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
WO2004096131A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
JP4679514B2 (ja) * 2003-04-24 2011-04-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
DE602004026047D1 (de) * 2003-04-24 2010-04-29 Merck Sharp & Dohme Hemmer der akt aktivität
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
CN1942470A (zh) * 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
EP1737843B1 (de) * 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Hemmer der akt aktivität
AU2005290081B2 (en) * 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006065601A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
CN101263126B (zh) * 2005-09-12 2013-11-20 株式会社半导体能源研究所 喹喔啉衍生物和使用它的发光元件，发光装置及电子设备
EP1978964A4 (de) 2006-01-24 2009-12-09 Merck & Co Inc Jak2-tyrosinkinase-hemmung
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007108403A1 (en) 2006-03-21 2007-09-27 Semiconductor Energy Laboratory Co., Ltd. Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2670767A1 (en) * 2006-12-06 2008-06-12 Merck & Co., Inc. Inhibitors of akt activity
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
US8178216B2 (en) * 2007-02-28 2012-05-15 Semiconductor Energy Laboratory Co., Ltd. Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2067778B1 (de) * 2007-12-03 2016-08-17 Semiconductor Energy Laboratory Co., Ltd. Quinoxalin-Derivat und lichtemittierendes Element, lichtemittierende Vorrichtung und elektronische Vorrichtung damit
JP5574598B2 (ja) * 2007-12-03 2014-08-20 株式会社半導体エネルギー研究所 キノキサリン誘導体、およびキノキサリン誘導体を用いた発光素子、発光装置、電子機器
CA2726358A1 (en) * 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2009255358A1 (en) * 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
WO2010088177A1 (en) * 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP2012517448A (ja) * 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
EP2405756B1 (de) 2009-03-12 2013-07-03 Merck Sharp & Dohme Corp. Hemmer der akt-aktivität
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
WO2011075517A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
EP2699567A1 (de) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
EP2548877A1 (de) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Gliedrige kondensierte Pyridinyl)benzamide als BTK-Inhibitoren
CN107245056A (zh) 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
EP2755657B1 (de) 2011-09-14 2017-11-29 Neupharma, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
WO2013049701A1 (en) 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2806874B1 (de) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxalin-oxy-phenyl derivate als Kinase-Inhibitoren
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
EP2863916B1 (de) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituierte pyridin-milz-tyrosinkinaseinhibitoren
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (de) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituierte imidazopyridine als hdm2 inhibitoren
WO2014114185A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
AU2014214326B2 (en) 2013-02-07 2018-07-05 Prexton Therapeutics Sa Substituted quinoxaline derivatives and their use as positive allosteric modulators of mGluR4
EP2988749B1 (de) 2013-04-26 2019-08-14 Merck Sharp & Dohme Corp. Thiazolsubstituierte aminopyridine als milztyrosinkinasehemmer
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3083560B1 (de) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazolsubstituierte aminoheteroaryle als milztyrosinkinasehemmer
EP3082809B1 (de) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk-hemmer
EP3082811B1 (de) 2013-12-20 2020-01-15 Merck Sharp & Dohme Corp. Btk-hemmer
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106628A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106629A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3795571B1 (de) 2018-07-02 2024-05-08 Shenzhen TargetRx, Inc. Alkynyl(hetero)aromatische verbindung zur hemmung der proteinkinaseaktivität
US11746110B2 (en) 2018-07-17 2023-09-05 Shenzhen Targetrx, Inc. Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
CN109518211B (zh) * 2019-01-08 2020-11-06 合肥工业大学 一种芳香偶酰类化合物的电化学合成方法
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
EP4076459B1 (de) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1384713A (fr) * 1962-11-24 1965-01-08 Kalle Ag Matériel d'électrophotographie
NL300539A (de) * 1962-11-24
DE3420039A1 (de) * 1984-05-29 1985-12-12 Hoechst Ag, 6230 Frankfurt 2,3-bis(dialkylaminophenyl)chinoxaline und ihre verwendung in elektrophotographischen aufzeichnungsmaterialien
IN166761B (de) 1987-04-10 1990-07-14 Hoechst India
JPS6457261A (en) 1987-08-28 1989-03-03 Alps Electric Co Ltd Photoconductive film and electrophotographic sensitive body using same
EP0397859A4 (en) 1987-11-12 1990-12-19 Terumo Kabushiki Kaisha Pyrazine derivatives and medicinal preparation containing same
GB2293380A (en) 1994-09-22 1996-03-27 Zeneca Ltd Pesticidal heterocyclic and phenyl compounds
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
AU1918299A (en) 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
JP2000309578A (ja) 1999-04-27 2000-11-07 Kyowa Hakko Kogyo Co Ltd キノキサリン誘導体
EP1345925B1 (de) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als proteinkinasehemmer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors

Also Published As

Publication number Publication date
EP1379251A4 (de) 2005-05-25
JP4361276B2 (ja) 2009-11-11
DE60227492D1 (de) 2008-08-21
US7034026B2 (en) 2006-04-25
AU2002252614B2 (en) 2006-09-14
EP1379251A1 (de) 2004-01-14
CA2442270C (en) 2009-09-08
EP1379251B1 (de) 2008-07-09
CA2442270A1 (en) 2002-10-24
JP2004525961A (ja) 2004-08-26
WO2002083138A1 (en) 2002-10-24
US20040143117A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
DE60227492D1 (de) Hemmstoffe der akt aktivität
EP1631548A4 (de) Hemmer der akt aktivität
CA2480800A1 (en) Inhibitors of akt activity
EP1622616A4 (de) Hemmer der akt aktivität
EP1620411A4 (de) Hemmer der akt aktivität
WO2003086279A3 (en) Inhibitors of akt activity
EP1558586A4 (de) Hemmer der akt aktivität
EP1737843A4 (de) Hemmer der akt aktivität
WO2006036395A3 (en) Inhibitors of akt activity
WO2004096130A3 (en) Inhibitors of akt activity
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
WO2002083675A3 (en) Inhibitors of akt activity
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
BG106585A (en) Kinase inhibitors as therapeutic agents
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HRP20000469B1 (hr) Biciklički heteroaromatični spojevi kao inhibitori protein -tirozin kinaze
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
ATE437872T1 (de) Proteinkinaseinhibitoren
BG106020A (en) Inhibitors of impdh enzyme
PT652868E (pt) Inibidores da fosfodiesterase do amp ciclico
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
MXPA04005809A (es) Inhibidores de proteinas quinasas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties